Oxford Biomedica Share Discussion Threads

[marcusl2] 29/9/2022 08:56

Armored CAR T Cells Break Through Immune Suppression in Solid Tumors

One of the hallmarks of the immunosuppressive microenvironment is the inhibitory factor Tgfß1, which paralyzes the function of existing and engineered T cells. Fraietta and his colleagues wanted to prevent these CAR T cells from being poisoned by Tgfß once they get into the tumor microenvironment. The researchers engineering CAR T cells to overexpress a dominant-negative Tgfß receptor, which binds the Tgfß1 ligand without activating the signaling pathway. Mice treated with these armored CAR T cells had significant increases in T cell proliferation and decreases in tumor burden.

[qnq] 29/9/2022 07:54

INSIDERS BUYING

[harry s truman] 28/9/2022 23:44

Interesting presentation about the Boston business

[harry s truman] 27/9/2022 19:03

James Miskin
Chief Technical Officer, Oxford Biomedica

[harry s truman] 27/9/2022 15:49

I realise that I'm about to curse this, but the price is rising this afternoon on good volume (212,415 as I type) and so if we close above 400p today then I shall say RNS tomorrow morning.

[harry s truman] 27/9/2022 11:22

Poonawalla is also going global with SII's vaccine manufacturing capabilities and has worked out partnerships with Oxford BioMedica in the United Kingdom and South Africa's Aspen Pharmacare in Africa.

SII is investing 50 million pounds in Oxford BioMedica to help fund the development of a plant that manufactures COVID-19 shots.

An agreement between SII and Aspen is to support the African health systems to be more resilient and independent and help improve health outcomes in ..

Read more at:

[harry s truman] 26/9/2022 19:16

Inside OxBox



Nice video

[harry s truman] 26/9/2022 19:13

Ahead of the 19th annual bioProcessUK conference (15-17 November, Edinburgh), we spoke to Simon Simpkins PhD, VP, Head of Operational Strategy at Oxford Biomedica about the company's digital future, where the foundational concept of good data management underpins all aspirations.

[marcusl2] 26/9/2022 15:09

Swap rates, which are the underlying rates that lenders use to price loans alongside the central Bank Rate, have surged. Five-year swaps have risen from 4pc last week to more than 5pc today – compared with 3pc in August and 0.7pc a year ago, according to analysis by broker SPF Private Clients.

[marcusl2] 26/9/2022 14:39

A lot of British companies must be looking very cheap to the Americans with the weak pound v dollar and low valuations atm.

[badger60] 26/9/2022 10:08

#3948
There seems to be a very unequal genetic distribution of brains and stupidity between bruvvers Diggle. Seems like Martin got far more than his share of the latter........
Perhaps watching the grinding of the value of a company in which you have a substantial holding down from nearly 1.5 BN mkt cap to under 350 Mio mkt cap in less than a year should also warrant a ditty from Bloomberg.
I'll start the ball rolling....Martin Diggle the Vulpes biotechnology fund manager has sat by and watched 1.2bn GBP being wiped off the value of OXB in less than a year......which is currently worth less than 350 Mio quid. Vulpes Investment Management is currently the largest shareholder owning 11% of the company's shares.(and probably owns a lot more if you know where to look).

[marcusl2] 26/9/2022 09:42

Trader who made billions in 2008 buys pound near all-time low
MON, SEP 26, 2022 - 4:29 PM UPDATED MON, SEP 26, 2022 - 4:30 PM
25689103H168885.jpg
The Artradis Fund Management office in Singapore in 2006. Stephen Diggle founded the firm in 2001. The firm went on to earn its name for lucrative bets in 2007 and 2008. PHOTO: BLOOMBERG
A FORMER hedge fund manager who shot to fame for a US$2.7 billion volatility trading gain during the global financial crisis is buying the pound on a day when the currency has slumped to an all-time low.

Stephen Diggle used 10 per cent of the assets of a “small fund” to buy sterling to finance investments in the UK, especially stocks of companies that have earnings in the greenback, but costs in the British currency, he said in an e-mail. He didn’t specify the name and size of the fund.

“I’m not calling a trading low. Who the hell knows?” said the Singapore-based investor. “But against a 5- or 10-year average, sterling is very cheap now.”

Investors are dumping the currency after British Chancellor of Exchequer Kwasi Kwarteng vowed to implement more tax cuts, risking sending the country’s inflation rate and government debt surging. Sterling sank the most since March 2020, at the outset of the Covid-19 pandemic.

Diggle co-founded volatility hedge fund Artradis Fund Management in 2001. Artradis earned its name for lucrative bets in 2007 and 2008. Later his family office, Vulpes Investment Management, invested in assets including biotechnology ventures, avocado orchards in New Zealand, German real estate and European rearmament firms, the stocks of which surged on the Russian invasion of Ukraine.

The sterling bet wasn’t just opportunistic currency trading, as the firm has investments in the UK that need the pound, Diggle wrote, adding that he doesn’t see

[badger60] 26/9/2022 03:56

Sell your OXB shares now, so that you can have something to burn to keep you warm for a day or so in winter.
If you own 1000 shares, try and get them sent to you in 1 share certificates. Alternatively you could always set fire to Diggle's gaff and toast a few marshmallows..........

[harry s truman] 25/9/2022 14:21

R21/Matrix-M in African Children Against Clinical Malaria Phase 3 trial



Estimated Primary Completion Date December 2022

[harry s truman] 25/9/2022 14:16

How soon do they have to start the ball rolling with manufacturing for a 2023 rollout?



2023 rollout

The R21 vaccine, developed at the University of Oxford’s Jenner Institute, is licensed for production by the Serum Institute of India (SII).

“We are already planning, in collaboration with our partners … to take a programmatic deployment of R21 from 2023 on a population of at least 250,000 children in Burkina Faso, in order to accelerate the agenda for the deployment of this vaccine on a large scale in Africa,” said Tinto.

He said SII was committed to producing at least 100-200 million doses of the R21 vaccine per year subject to the WHO issuing a recommendation for its deployment. “This will supplement the only vaccine currently recommended by WHO (RTS,S) whose current production capacity cannot meet global demand,” Tinto added.

[philh75] 25/9/2022 10:22

Gigabit,
They also said on the webcast that the right sizing would be done through attrition, so not redundancies.

[badger60] 25/9/2022 10:18

Your on the tight track but I would go for a 98% downsize to make it viable......Culling all the cretin senior management first.....and Diggle.

[mint1111] 25/9/2022 10:14

Sharellog #3943Yep, downsize OXB by 95 % and your idea would probably work well........

[sharelog3] 25/9/2022 09:22

Gigabit. It could also mean having the right amount of and the right people to do the job now and for future contracts.

[gigabit] 25/9/2022 07:25

Interim statement said 'cost control including right-sizing of headcount'. Is that not a euphemism for redundancy?